🧠 Cagrilintide — The Next-Gen Appetite Peptide

⭐

🔥

Daily Deep Dive:

Cagrilintide is a long-acting amylin analog — a hormone that works alongside insulin and GLP-1 to regulate appetite, digestion, and glucose levels.

Unlike GLP-1s, it targets amylin receptors in the brain’s satiety centers for powerful appetite suppression and smoother glucose control.

⚙️

How It Works

🧩 Delays gastric emptying → keeps food in your stomach longer
🧠 Activates satiety centers → reduces hunger and food noise
💉 Improves post-meal glucose control
⚡ Synergizes with GLP-1s (Semaglutide/Tirzepatide) → stronger results together

📊

Research Data (Novo Nordisk | Lancet 2021)

706 adults studied
Cagrilintide alone: ~10.8% mean weight loss in 26 weeks
Cagrilintide + Semaglutide: up to 17% average weight loss
Side effects: mild nausea, constipation, fullness (usually temporary)

💉

Research Dosing used in trials (Educational Use)

For research discussion only

Reconstitute with acidic solution (pH ~4) for stability (bac water generally tends to be fine)
Start: 0.1 mg once weekly, titrate every 2–3 weeks
Maintenance: 1.2–2.4 mg once weekly
Common combo: Cagrilintide + Semaglutide (1–2.4 mg/week)

💥

Why It’s Exciting

Shuts down food noise
Extends fullness between meals
Enhances GLP-1 results without extra side effects
May help preserve lean mass while dieting

🔍

Takeaway

Cagrilintide represents a new frontier in metabolic peptides — working through amylin instead of GLP-1, yet delivering insane synergy when paired together.

65 comments